DefiniGEN is a game-changing company, that will re-define in vitro liver models by allowing large-scale screening of therapeutics and hepatotoxicity studies. Based at the Babraham Research Campus in Cambridge, UK, DefiniGEN’s technology allows the bulk generation of hepatocyte-like cells (HLCs) with superior purity, improved functionality, and high hepatic relevance.
Overcoming the limitations of primary human hepatocytes as well as liver cancer cell lines, and by applying CRISPR-based gene editing, DefiniGEN’s iPSCs are used to generate HLCs that replicate hepatic disease phenotypes across a wide range of conditions, providing a unique platform for the study of both rare monogenic and multifactorial liver diseases. Crucially, our approach introduces, for the first time, healthy HLCs of the highest hepatic function for predictive toxicology studies, in addition to novel liver disease models to markets of unmet clinical need, downstream mitigating the failure risks in costly late-stage drug development.
Our mission is to navigate drug development programs through uncharted waters, minimizing failure risks while driving costs down, and paving the way for a more efficient and effective future in the world of drug discovery.